Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free VYNE Stock Alerts

VYNE Therapeutics (VYNE) Competitors

VYNE Therapeutics logo
$0.66 +0.00 (+0.38%)
Closing price 06/8/2026 04:00 PM Eastern
Extended Trading
$0.66 +0.00 (+0.06%)
As of 06/8/2026 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VYNE vs. ANIX, RLYB, LIXT, ICCC, and LONA

Should you buy VYNE Therapeutics stock or one of its competitors? MarketBeat compares VYNE Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VYNE Therapeutics include Anixa Biosciences (ANIX), Rallybio (RLYB), Lixte Biotechnology (LIXT), ImmuCell (ICCC), and Athira Pharma (LONA). These companies are all part of the "pharmaceutical products" industry.

How does VYNE Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Anixa Biosciences has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

In the previous week, Anixa Biosciences' average media sentiment score of 0.00 equaled VYNE Therapeutics'average media sentiment score.

Company Overall Sentiment
Anixa Biosciences Neutral
VYNE Therapeutics Neutral

Anixa Biosciences has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Anixa Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anixa BiosciencesN/A -70.95% -62.53%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anixa Biosciences has higher earnings, but lower revenue than VYNE Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anixa Biosciences$210K392.78-$10.93M-$0.33N/A
VYNE Therapeutics$570K38.53-$26.48M-$0.38N/A

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 245.53%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anixa Biosciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Anixa Biosciences beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.

How does VYNE Therapeutics compare to Rallybio?

VYNE Therapeutics (NASDAQ:VYNE) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rallybio has higher revenue and earnings than VYNE Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$570K38.53-$26.48M-$0.38N/A
Rallybio$860K98.05-$8.98M-$4.34N/A

In the previous week, Rallybio had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Rallybio and 0 mentions for VYNE Therapeutics. Rallybio's average media sentiment score of 0.42 beat VYNE Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the news media.

Company Overall Sentiment
VYNE Therapeutics Neutral
Rallybio Neutral

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, suggesting that its share price is 189% less volatile than the broader market.

Rallybio has a net margin of -911.07% compared to VYNE Therapeutics' net margin of -4,726.21%. Rallybio's return on equity of -55.79% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VYNE Therapeutics-4,726.21% -70.42% -63.46%
Rallybio -911.07%-55.79%-51.48%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Rallybio beats VYNE Therapeutics on 10 of the 14 factors compared between the two stocks.

How does VYNE Therapeutics compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Lixte Biotechnology has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

In the previous week, Lixte Biotechnology had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Lixte Biotechnology and 0 mentions for VYNE Therapeutics. Lixte Biotechnology's average media sentiment score of 0.68 beat VYNE Therapeutics' score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
Lixte Biotechnology Positive
VYNE Therapeutics Neutral

Lixte Biotechnology has higher earnings, but lower revenue than VYNE Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/A-$6.01M-$1.13N/A
VYNE Therapeutics$570K38.53-$26.48M-$0.38N/A

Lixte Biotechnology has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Lixte Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Lixte BiotechnologyN/A -134.91% -95.61%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

VYNE Therapeutics beats Lixte Biotechnology on 8 of the 13 factors compared between the two stocks.

How does VYNE Therapeutics compare to ImmuCell?

VYNE Therapeutics (NASDAQ:VYNE) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

ImmuCell has a net margin of -1.82% compared to VYNE Therapeutics' net margin of -4,726.21%. ImmuCell's return on equity of -1.88% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VYNE Therapeutics-4,726.21% -70.42% -63.46%
ImmuCell -1.82%-1.88%-1.22%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
ImmuCell
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

In the previous week, VYNE Therapeutics' average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company Overall Sentiment
VYNE Therapeutics Neutral
ImmuCell Neutral

ImmuCell has higher revenue and earnings than VYNE Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$570K38.53-$26.48M-$0.38N/A
ImmuCell$27.64M3.18-$1.04M-$0.06N/A

Summary

ImmuCell beats VYNE Therapeutics on 7 of the 12 factors compared between the two stocks.

How does VYNE Therapeutics compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Athira Pharma has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Athira PharmaN/A -381.01% -225.74%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

VYNE Therapeutics has higher revenue and earnings than Athira Pharma. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A-$105.61M-$5.21N/A
VYNE Therapeutics$570K38.53-$26.48M-$0.38N/A

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Athira Pharma presently has a consensus price target of $15.00, suggesting a potential upside of 74.62%. Given Athira Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Athira Pharma is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Athira Pharma has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, Athira Pharma had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Athira Pharma and 0 mentions for VYNE Therapeutics. Athira Pharma's average media sentiment score of 0.00 equaled VYNE Therapeutics'average media sentiment score.

Company Overall Sentiment
Athira Pharma Neutral
VYNE Therapeutics Neutral

Summary

Athira Pharma and VYNE Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYNE vs. The Competition

Export
MetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.88M$2.96B$6.48B$11.99B
Dividend YieldN/A1.70%2.67%5.58%
P/E Ratio-1.7317.6823.6923.74
Price / Sales38.53302.68513.81108.85
Price / CashN/A56.1726.9937.25
Price / Book0.793.8310.416.78
Net Income-$26.48M$75.85M$3.57B$337.51M
7 Day Performance-2.57%-2.00%0.28%-2.34%
1 Month Performance-0.30%-5.85%3.27%1.88%
1 Year Performance-31.32%14.03%22.25%25.55%

VYNE Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYNE
VYNE Therapeutics
0.6437 of 5 stars		$0.66
+0.4%		N/A-34.1%$21.88M$570KN/A30
ANIX
Anixa Biosciences
1.9783 of 5 stars		$2.55
-5.6%		$8.50
+233.3%		-10.9%$90.53M$210KN/A5
RLYB
Rallybio
1.2741 of 5 stars		$16.23
-3.8%		N/A+403.5%$89.38M$860KN/A40
LIXT
Lixte Biotechnology
0.5514 of 5 stars		$7.04
-2.4%		N/A+400.1%$89.28MN/AN/A4
ICCC
ImmuCell
0.4697 of 5 stars		$9.79
+1.2%		N/A+48.5%$87.48M$27.64MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VYNE) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel